Cowen Maintains Positive View on Axsome Therapeutics (AXSM) Despite PDUFA Delay
Tweet Send to a Friend
Cowen analyst Joseph Thome reiterated an Outperform rating and $125.00 price target on Axsome Therapeutics (NASDAQ: AXSM) after the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
